Holdout juror in Lindsay Clancy case says he was sure of guilt
The lone holdout juror in the Lindsay Clancy trial said he was convinced of her guilt but felt the other jurors would not hear him out, according to a statement released by his lawyer.
Medicine & Biotech
Clinical AI, drug discovery, devices, and regulatory approvals.
RFK Jr. Defends Vaccine Skepticism at His Former Group's Conference
The HHS secretary appeared before the anti-vaccine nonprofit he helped create and renewed his criticism of vaccines, with one outlet noting the backdrop of a Pennsylvania measles outbreak.
Opdivo Makers Challenge Amgen's Biosimilar Ahead of FDA Ruling
Bristol Myers Squibb and Ono are contesting Amgen's biosimilar application as the FDA nears a decision on the first copy of the blockbuster cancer drug.
Cellares and GenomeFrontier Partner to Automate Virus-Free CAR-T Production
The collaboration will test whether Cellares' automated Cell Shuttle platform can efficiently manufacture virus-free CAR-T therapies.
FDA approves Ultragenyx gene therapy Fayuvi for Sanfilippo syndrome type A
The first treatment for the underlying cause of Sanfilippo syndrome type A wins approval, marking Ultragenyx's second gene therapy.
Gilead's CEO says oncology and inflammation push has reached 'critical mass'
Gilead's CEO says the company's diversification into oncology and inflammation has reached a critical mass after a series of acquisitions.
Novartis Pays $125M for Sironax Blood-Brain Barrier Platform
The deal gives Novartis a way to move large-molecule drugs into the central nervous system, at a time when its neuroscience pipeline has suffered setbacks.
Roche and Dualitas team up to screen 300,000 bispecific combos
A deal worth up to $1 billion will let Roche tap Dualitas' high-throughput screening platform for new immunology and inflammation therapies.
Novo bets $1.4B on oral macrocycles, adds three obesity drugs from Kallyope
Two new deals show Novo's push to replenish its cardiometabolic pipeline with early-stage oral therapies.
North Immunology Goes Public via Reverse Merger to Advance Eczema Drug
The inflammation biotech is taking a bispecific antibody for atopic dermatitis public through a $180M reverse merger with Aethlon Medical.
New U.S. China Investment Rules Likely to Spare Most Pharma Licensing Deals
Both Fierce Pharma and STAT report that draft U.S. Treasury rules will probably preserve most licensing deals for Chinese-developed drugs, easing a major industry worry.
Eli Lilly’s World Alzheimer’s Day Effort Sends Produce to Underserved Seniors
Eli Lilly will distribute 13,500 boxes of brain-healthy fresh produce and educational materials to underserved U.S. seniors for World Alzheimer’s Day.
Trialynx Wins DPHARM Idol Disrupt 2026 Award
Trialynx took home the DPHARM Idol Disrupt award at the 2026 DPHARM conference, according to a Fierce Pharma partner-content piece.
Sun Pharma and Christian Siriano launch alopecia areata education campaign
The 'Regrowth Restyled' campaign pairs a fashion designer with patients to spotlight hair regrowth, shifting focus from loss to recovery.
Ex-Publicis Health Media CEO Andrea Palmer to Lead Assembled Intelligence
Andrea Palmer, former CEO of Publicis Health Media, has been named CEO of Assembled Intelligence, the agency launched by Minds + Assembly to unify its recent acquisitions.
Reckitt to Spend $600M on U.S. R&D Hub and Manufacturing Expansion
The Lysol and Mucinex maker is investing in domestic R&D and expanding its largest plant by half.
FDA approves Lilly's Inluriyo-Verzenio combo in oral SERD push
Eli Lilly's oral SERD Inluriyo is now approved in combination with Verzenio, a move that escalates competition among oral SERD therapies.
Legend Biotech names Novartis veteran Ingrid Zhang as permanent CEO
The CAR-T cell therapy maker has filled its top job with a 15-year Novartis executive as it pushes to expand commercial reach.